# Study of ODX (OsteoDex) in Multiple Myeloma

> **NCT06616389** · PHASE1,PHASE2 · RECRUITING · sponsor: **DexTech Medical AB** · enrollment: 12 (estimated)

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** ODX (Osteodex)

## Key facts

- **NCT ID:** NCT06616389
- **Lead sponsor:** DexTech Medical AB
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-11-29
- **Primary completion:** 2026-01-30
- **Final completion:** 2026-01-30
- **Target enrollment:** 12 (ESTIMATED)
- **Last updated:** 2025-08-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06616389

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06616389, "Study of ODX (OsteoDex) in Multiple Myeloma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06616389. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*